Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 7. Genetic alterations of RPL22L1 in LUAD. (A) This study examines the presence of structure variants, mutations, and copy number alterations in the gene RPL22L1. (B) The aim of this research is to provide a comprehensive description of the various types, number, and location of mutations occurring in the gene RPL22L1. (C) The frequency of gene alterations is assessed in both the RPL22L1 altered and unaltered groups, in order to determine their association with the gene RPL22L1. (D) A comparative analysis of progression free survival is conducted between the RPL22L1 altered group and the RPL22L1 unaltered group in pan cancer cases.